---
title: "Solid Power (SLDP) Receives a Buy from Needham"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285362658.md"
description: "Needham analyst Chris Pierce has reiterated a Buy rating on Solid Power (SLDP) with a price target of $7.00. H.C. Wainwright also maintains a Buy rating with the same price target. Pierce focuses on the Consumer Cyclical sector and has an average return of -6.0% with a 39.24% success rate on his stock recommendations."
datetime: "2026-05-06T10:58:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285362658.md)
  - [en](https://longbridge.com/en/news/285362658.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285362658.md)
---

# Solid Power (SLDP) Receives a Buy from Needham

Needham analyst Chris Pierce reiterated a Buy rating on Solid Power today and set a price target of $7.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Pierce covers the Consumer Cyclical sector, focusing on stocks such as Sonic Automotive, Carvana Co, and Lucid Group. According to TipRanks, Pierce has an average return of \-6.0% and a 39.24% success rate on recommended stocks.

In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.

### Related Stocks

- [SLDP.US](https://longbridge.com/en/quote/SLDP.US.md)
- [SAH.US](https://longbridge.com/en/quote/SAH.US.md)
- [CVNA.US](https://longbridge.com/en/quote/CVNA.US.md)
- [LCID.US](https://longbridge.com/en/quote/LCID.US.md)
- [SLDPW.US](https://longbridge.com/en/quote/SLDPW.US.md)

## Related News & Research

- [Why SanDisk stock rebounded today](https://longbridge.com/en/news/293246949.md)
- [Rollins: Near-Term Weakness Seen as Transitory, Long-Term Pest Control Growth Supports Buy Rating](https://longbridge.com/en/news/293529972.md)
- [Analyst Reiterates Buy on Mobileye as Strong EyeQ/SuperVision Sales, Higher 2026 Guidance and Robotaxi Strategy Support $13 Price Target](https://longbridge.com/en/news/293739738.md)
- [Pacira Therapeutics: PCRX-201 Progress and Key ASCEND Catalysts Support Buy Rating; $32 Price Target Reaffirmed](https://longbridge.com/en/news/293960582.md)
- [Analyst Reiterates Buy on AppFolio as Modestly Raised 2026 Guidance and Premium Valuation Reflect Sustained High-Teens Growth and Margin Expansion](https://longbridge.com/en/news/293683800.md)